PubRank

Ezekiel J Emanuel

Author PubWeight™ 162.74‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Affordable Care Act and the future of clinical medicine: the opportunities and challenges. Ann Intern Med 2010 9.59
2 Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005 8.25
3 Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol 2006 5.40
4 Principles for allocation of scarce medical interventions. Lancet 2009 4.55
5 Ethical issues concerning research in complementary and alternative medicine. JAMA 2004 4.48
6 The obligation to participate in biomedical research. JAMA 2009 4.34
7 Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 2002 3.62
8 Shared decision making to improve care and reduce costs. N Engl J Med 2013 3.48
9 The cost of marginal medicine is too high. MedGenMed 2005 3.33
10 Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit. JAMA 2005 3.14
11 The cost of institutional review boards in academic medical centers. N Engl J Med 2005 3.06
12 Prescribing "placebo treatments": results of national survey of US internists and rheumatologists. BMJ 2008 2.84
13 Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol 2006 2.72
14 Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality. J Clin Oncol 2004 2.52
15 Medicare's requirement for research participation as a condition of coverage: is it ethical? JAMA 2006 2.43
16 Research with stored biological samples: what do research participants want? Arch Intern Med 2005 2.43
17 The prognosis for changes in end-of-life care after the Schiavo case. Health Aff (Millwood) 2005 2.40
18 Patients' views on financial conflicts of interest in cancer research trials. N Engl J Med 2006 2.29
19 Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA 2003 2.28
20 Ethical guidance on the use of life-sustaining therapies for patients with Ebola in developed countries. Ann Intern Med 2014 2.19
21 US health aid beyond PEPFAR: the Mother & Child Campaign. JAMA 2008 2.17
22 The 50th anniversary of the Declaration of Helsinki: progress but many remaining challenges. JAMA 2013 2.16
23 Community permission for medical research in developing countries. Clin Infect Dis 2005 2.01
24 The standard of care debate: can research in developing countries be both ethical and responsive to those countries' health needs? Am J Public Health 2004 1.88
25 The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA 2005 1.83
26 The ethics of paying for children's participation in research. J Pediatr 2002 1.80
27 What is a "minor" increase over minimal risk? J Pediatr 2005 1.79
28 Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med 2008 1.74
29 Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol 2008 1.71
30 Will physicians lead on controlling health care costs? JAMA 2013 1.71
31 Health care reform and cost control. N Engl J Med 2010 1.66
32 Ethics. The ethics of international research with abandoned children. Science 2007 1.65
33 Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research. J Clin Oncol 2007 1.65
34 Why patients continue to participate in clinical research. Arch Intern Med 2008 1.62
35 Ending concerns about undue inducement. J Law Med Ethics 2004 1.55
36 Health care reform: why? What? When? Health Aff (Millwood) 2005 1.50
37 Regional ethics organizations for protection of human research participants. Nat Med 2004 1.48
38 Can primary care visits reduce hospital utilization among Medicare beneficiaries at the end of life? J Gen Intern Med 2008 1.47
39 Improving access to health care: a consensus ethical framework to guide proposals for reform. Hastings Cent Rep 2007 1.47
40 Access and ability to pay: the ethics of a tiered health care system. Arch Intern Med 2007 1.46
41 A historic moment for open science: the Yale University Open Data Access project and medtronic. Ann Intern Med 2013 1.45
42 Can the United States buy better advance care planning? Ann Intern Med 2014 1.41
43 ASCO core values. J Clin Oncol 2006 1.40
44 Quality-improvement research and informed consent. N Engl J Med 2008 1.40
45 Does random treatment assignment cause harm to research participants? PLoS Med 2006 1.39
46 The transparency imperative. Ann Intern Med 2013 1.39
47 The moral duty to buy health insurance. JAMA 2012 1.38
48 Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002 1.37
49 Tier 4 drugs and the fraying of the social compact. N Engl J Med 2008 1.16
50 The quality of informed consent in a clinical research study in Thailand. IRB 2005 1.13
51 PEPFAR and maximizing the effects of global health assistance. JAMA 2012 1.12
52 Single- vs multiple-fraction radiotherapy for bone metastases from prostate cancer. JAMA 2013 1.11
53 Evaluating the risks of clinical research. JAMA 2010 1.09
54 Alternative medicine research in clinical practice: a US national survey. Arch Intern Med 2009 1.07
55 Risks and benefits associated with novel phase 1 oncology trial designs. Cancer 2007 1.07
56 Using Behavioral Economics to Design Physician Incentives That Deliver High-Value Care. Ann Intern Med 2015 1.01
57 Clarifying confusions about coercion. Hastings Cent Rep 2005 1.01
58 Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. BMJ 2004 0.98
59 Who's caring for whom? Differing perspectives between seriously ill patients and their family caregivers. Am J Hosp Palliat Care 2006 0.96
60 Survey of oncologists about shortages of cancer drugs. N Engl J Med 2013 0.95
61 The general agreement on trade in services: implications for health policymakers. Health Aff (Millwood) 2004 0.94
62 Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study. AIDS Res Hum Retroviruses 2006 0.94
63 Why well-insured patients should demand value-based insurance benefits. JAMA 2007 0.93
64 Media exposure and tobacco, illicit drugs, and alcohol use among children and adolescents: a systematic review. Subst Abus 2010 0.92
65 Considering usual medical care in clinical trial design. PLoS Med 2009 0.91
66 The ethics of not hiring smokers. N Engl J Med 2013 0.91
67 Circumcision and HIV prevention research: an ethical analysis. Lancet 2006 0.90
68 The current state of medical school education in bioethics, health law, and health economics. J Law Med Ethics 2008 0.90
69 Patterns of care studies: creating "an environment of watchful concern". J Clin Oncol 2003 0.90
70 Depression, euthanasia, and improving end-of-life care. J Clin Oncol 2005 0.89
71 Institutional review board review of multicenter studies. Ann Intern Med 2007 0.88
72 Advance directives and cost savings: greater clarity and perpetual confusion. Arch Intern Med 2012 0.85
73 Reengineering US health care. JAMA 2013 0.85
74 The ethics of research in developing countries: assessing voluntariness. Lancet 2005 0.84
75 Overcoming the pricing power of hospitals. JAMA 2012 0.84
76 A consent form template for phase I oncology trials. IRB 2009 0.84
77 Informed consent: practices and views of investigators in a multinational clinical trial. IRB 2006 0.83
78 Does the evidence make a difference in consumer behavior? Sales of supplements before and after publication of negative research results. J Gen Intern Med 2008 0.82
79 Benefits and burdens of participation in a longitudinal clinical trial. J Empir Res Hum Res Ethics 2009 0.82
80 Nursing home residence confounds gender differences in Medicare utilization an example of Simpson's paradox. Womens Health Issues 2010 0.82
81 Toward accountable cancer care. JAMA Intern Med 2013 0.81
82 Research benefits for hypothetical HIV vaccine trials: The views of Ugandans in the Rakai District. IRB 2008 0.81
83 Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali. Am J Trop Med Hyg 2010 0.80
84 What does a hip replacement cost?: the transparency imperative in 2013. Comment on "Obtaining consumer prices from US hospitals for a common surgical procedure". JAMA Intern Med 2013 0.80
85 Religion, clinicians, and the integration of complementary and alternative medicines. J Altern Complement Med 2009 0.79
86 A communitarian health-care package. Responsive Community 1993 0.79
87 Factors that influence practitioners' interpretations of evidence from alternative medicine trials: a factorial vignette experiment embedded in a national survey. Med Care 2010 0.78
88 Living wills: are durable powers of attorney better? Hastings Cent Rep 2005 0.78
89 The ethics of research on enhancement interventions. Kennedy Inst Ethics J 2010 0.78
90 Is there coercion or undue inducement to participate in health research in developing countries? An example from Rakai, Uganda. J Clin Ethics 2009 0.77
91 Institutional review board reform. N Engl J Med 2002 0.76
92 Technology licensing: lessons from the US experience. JAMA 2005 0.76
93 Reconsidering the Declaration of Helsinki - Author' s reply. Lancet 2013 0.75
94 Use of Life-Sustaining Therapies for Patients With Ebola Virus Disease. Ann Intern Med 2015 0.75
95 Reductions in funding for medical research--reply. JAMA 2013 0.75
96 "Physician-assisted suicide among Oregon cancer patients": a fading issue. J Clin Ethics 2006 0.75
97 Standing by our principles: meaningful guidance, moral foundations, and multi-principle methodology in medical scarcity. Am J Bioeth 2010 0.75
98 Physicians advising investment firms. JAMA 2005 0.75
99 Reforming American Medical Education. Milbank Q 2017 0.75
100 Eight is too many: the case against octuplets. New Repub 1999 0.75
101 Conserving scarce resources: willingness of health insurance enrollees to choose cheaper options. J Law Med Ethics 2004 0.75
102 The Case for Resource Sensitivity: Why It Is Ethical to Provide Cheaper, Less Effective Treatments in Global Health. Hastings Cent Rep 2017 0.75
103 Euthanasia and the care of cancer patients. J Clin Oncol 1994 0.75
104 Volume Increases and Shared Decision-making in Joint Replacement Bundles. Ann Surg 2017 0.75
105 What are bioethicists doing about health care reform? Hastings Cent Rep 2008 0.75
106 Review of the American College of Physicians Ethics Manual, Sixth Edition. Ann Intern Med 2012 0.75
107 The beginning of the end of principlism. Hastings Cent Rep 1995 0.75
108 New strategies for aligning physicians with health system incentives. Am J Manag Care 2016 0.75
109 The blossoming of bioethics at NIH. Kennedy Inst Ethics J 1998 0.75
110 Legal reforms necessary to promote delivery system innovation. JAMA 2008 0.75
111 Moving risk to physicians. Am J Manag Care 2015 0.75
112 Is health care a commodity? Lancet 1997 0.75
113 Assisted suicide? Not in my state. N Y Times Web 1997 0.75
114 End-of-life care: the authors respond. Health Aff (Millwood) 2005 0.75
115 Managing end-of-life care: comparing the experiences of terminally Ill patients in managed care and fee for service. J Am Geriatr Soc 2002 0.75
116 Price and utilization: why we must target both to curb health care costs. Ann Intern Med 2012 0.75
117 What is the great benefit of legalizing euthanasia or physician-assisted suicide? Ethics 1999 0.75
118 The painful truth about euthanasia. Wall St J (East Ed) 1997 0.75